<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8E8DBD7B-7AB4-4A70-86C0-C24FA4DA99CB"><gtr:id>8E8DBD7B-7AB4-4A70-86C0-C24FA4DA99CB</gtr:id><gtr:name>Allergy Therapeutics</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Medicine and Biomedical Science</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8E8DBD7B-7AB4-4A70-86C0-C24FA4DA99CB"><gtr:id>8E8DBD7B-7AB4-4A70-86C0-C24FA4DA99CB</gtr:id><gtr:name>Allergy Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/16373A12-6246-471D-B513-52AFCD627619"><gtr:id>16373A12-6246-471D-B513-52AFCD627619</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Sabroe</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G116%2F170"><gtr:id>515AAF08-9C11-41F6-9B02-C692EB4170F5</gtr:id><gtr:title>The control of Toll-like receptor (TLR)-mediated neutrophil activation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G116/170</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>A white blood cell, the neutrophil, is a principal defence against infection. Its recruitment to, and activation within, tissues results in the removal of microbes and survival of the host. Unfortunately, inappropriate neutrophil activation also occurs in many lung diseases, contributing to tissue damage, and ultimately ill health or even death. This project will develop a deeper understanding of the ways in which neutrophils are activated by microbial products, which are sensed by the neutrophil using proteins called Toll-like receptors (TLRs).
We propose that neutrophils recruited into tissue will show altered patterns of TLR responses, which will affect their tissue positioning and activation. Our first set of studies will determine patterns of neutrophil responses in tissue cells compared with those in the peripheral blood, using a range of established and novel assays of neutrophil activation. We will subsequently investigate the molecular mechanisms underpinning altered cell phenotype at the level of intracellular signalling. We will determine how TLR signalling affects subsequent cell migration and activation driven by other neutrophil activators, principally chemoattractants.
We hypothesise that neutrophil responses to TLR agonists will be determined by trafficking of the TLR to the cell membrane and specific intracellular compartments, and will explore this in primary neutrophils in collaboration with Prof Smythe (Sheffield University). We will determine if activated TLRs can recycle to the cell membrane, and if control of recycling provides further mechanisms to regulate neutrophil responses. In parallel, we will determine the molecular pathways resulting in TLR internalisation and reexpression in cell lines. We propose that the box 3 region of the intracellular TIR domain may be involved in trafficking of receptors, and we will use strategies involving receptor mutagenesis and construction of chimaeric proteins to determine the importance of these regions in receptor function. 
Finally, we hypothesise that neutrophils become rapidly unresponsive to TLR agonists, which we propose is part of a mechanism preventing their excessive activation at inflammatory sites. We have developed novel preliminary data describing the cellular and molecular mechanisms causing neutrophils to become unresponsive, and will study these systems in more detail to determine if they represent therapeutic targets controlling neutrophil activation. We will investigate whether other inflammatory products also serve to limit neutrophil inflammation by inhibiting TLR activation in these cells.
These studies will identify new ways of targeting neutrophilic activation in inflammatory disease with wide-ranging therapeutic consequences for respiratory diseases including asthma and COPD.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1144482</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Allergy Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Analysis of novel TLR antagonist</gtr:description><gtr:id>2BF6BF69-78FD-45CB-8A02-06D4751397CD</gtr:id><gtr:impact>Collaboration resulting in description of new reagent as a novel TLR antagonist. Likely to be taken further in the future.</gtr:impact><gtr:outcomeId>D7F69F42A80-1</gtr:outcomeId><gtr:partnerContribution>Collaboration resulting in description of new reagent as a novel TLR antagonist. Likely to be taken further in the future.</gtr:partnerContribution><gtr:piContribution>Collaboration resulting in description of new reagent as a novel TLR antagonist. Likely to be taken further in the future.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>National Science Week School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>DBC01312-4C97-4D69-B83F-63262E2DB938</gtr:id><gtr:impact>Approx 120 students aged 14-16 attended a talk on airways inflammation and asthma, given by me and my group (including LCP who was funded by this fellowship).

Generated interest by school children in asthma and inflammation</gtr:impact><gtr:outcomeId>rWjkCd3dTgL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talks at International Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>893D953F-440E-4647-BFBD-064905CB580E</gtr:id><gtr:impact>'Targeting TLRs'. New Drugs for Asthma and COPD, Brompton Hospital 2008. 'The networks that regulate innate and adaptive immunity in asthma and COPD'. Invited talk for the joint BTS/BALR symposium at the British Thoracic Society Winter meeting, London 2007. 8th Annual Lund COPD Symposium April 2007 talk title 'Integration of the innate and adaptive immune responses in COPD'. Chair of Session and speaker at British Society for Allergy and Clinical Immunology, July 2007. Talk title 'Inflammatory Networks of Asthma' 'Toll-like receptors:&amp;nbsp; Potential therapeutic aspects'. Joint British Thoracic Society/ British Society for Allergy and Clinical Immunology, BTS Winter meeting, Dec 2006

Generated useful collaborations and raised importance of field</gtr:impact><gtr:outcomeId>A39AA2B4CE2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>141000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK Project Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>3A32DB2C-147B-4D5E-A7CA-9976F4FF6A2A</gtr:id><gtr:outcomeId>3ECFEAC04A10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Project Grant</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>D90A62EE-8C5E-4621-B713-DB6FF4831A4B</gtr:id><gtr:outcomeId>41F2D82B2080</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sheffield Hospitals Charitable Trust, Project Grant</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Sheffield Hospitals Charity</gtr:fundingOrg><gtr:id>4392A13E-BA94-4A2D-B45F-B3152A8FE212</gtr:id><gtr:outcomeId>91BDFC10FC00</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>281482</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (Inhibiting TLR signalling by disruption of membrane microdomains)</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>D8BD092E-7BF0-430E-B6CC-7E3FF045072B</gtr:id><gtr:outcomeId>psHf4eCHMTG0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK/MRC Capacity-building studentship</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>20D4BC15-BFA8-4B9E-99BC-855BACA4D68B</gtr:id><gtr:outcomeId>FFC03B1D2C70</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>712000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C1E26ACF-C48C-4E37-B99F-919ED76F1527</gtr:id><gtr:outcomeId>8105F272D8B0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A6CD30DB-DE1E-4560-9229-D6025B5E35A1</gtr:id><gtr:title>9alpha,11beta-PGF2 and its stereoisomer PGF2alpha are novel agonists of the chemoattractant receptor, CRTH2.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50c2a528a87bc40c7305525cdd8d0c79"><gtr:id>50c2a528a87bc40c7305525cdd8d0c79</gtr:id><gtr:otherNames>Sandig H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>31EB4A82DC8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>628BF1DD-C5D3-474C-9E6D-68CED50DD16A</gtr:id><gtr:title>Potentiation of TLR4 signalling by plasmin activity.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af9cf1603ba8689b71fea78eea52b3db"><gtr:id>af9cf1603ba8689b71fea78eea52b3db</gtr:id><gtr:otherNames>Ward JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>15BB9066715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD774A00-DDC7-4F98-B9B5-E631C29DB023</gtr:id><gtr:title>Targeting the networks that underpin contiguous immunity in asthma and chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae7979792fa37c6ccd925b8ea628d6f"><gtr:id>fae7979792fa37c6ccd925b8ea628d6f</gtr:id><gtr:otherNames>Sabroe I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>C04991409D5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D54FABBE-06E3-44F0-85DD-51E71AFDBD12</gtr:id><gtr:title>A phosphatidylserine species inhibits a range of TLR- but not IL-1beta-induced inflammatory responses by disruption of membrane microdomains.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce6d578dd442ed283224a3e514f486d3"><gtr:id>ce6d578dd442ed283224a3e514f486d3</gtr:id><gtr:otherNames>Parker LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>921DEE0E6FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>093910F0-0399-4A83-B963-2E09F5B21163</gtr:id><gtr:title>Ex vivo-expanded bone marrow CD34+ derived neutrophils have limited bactericidal ability.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bceed23e31a217e9f8ecea149a8b7e3"><gtr:id>2bceed23e31a217e9f8ecea149a8b7e3</gtr:id><gtr:otherNames>Dick EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>4BA59CEDDD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E401DEA2-878E-4FE2-B9EC-C8EE65274714</gtr:id><gtr:title>Subversion of a lysosomal pathway regulating neutrophil apoptosis by a major bacterial toxin, pyocyanin.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/701f833924554817b65818c42b70aa53"><gtr:id>701f833924554817b65818c42b70aa53</gtr:id><gtr:otherNames>Prince LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>C911C492344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E52CF7EA-07E8-4A97-B42D-53C27DF5BEE2</gtr:id><gtr:title>Role of interleukin-1 and MyD88-dependent signaling in rhinovirus infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dc1243ad2ca64eff23f5b38410209e0"><gtr:id>7dc1243ad2ca64eff23f5b38410209e0</gtr:id><gtr:otherNames>Stokes CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>M862nFfevrE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C363EA2E-1B1E-483F-8969-59A3070B0286</gtr:id><gtr:title>T lymphocytes expressing CCR3 are increased in allergic rhinitis compared with non-allergic controls and following allergen immunotherapy.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b4a28a9efea6aa730de4f1c70ba63b4"><gtr:id>0b4a28a9efea6aa730de4f1c70ba63b4</gtr:id><gtr:otherNames>Francis JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>1860ED874F4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDCD469C-4006-4368-90BF-ABD7C5F15D47</gtr:id><gtr:title>&amp;quot;Dirty little secrets&amp;quot;--endotoxin contamination of recombinant proteins.</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c812bdf76a99b3a911c800fbe847e7a5"><gtr:id>c812bdf76a99b3a911c800fbe847e7a5</gtr:id><gtr:otherNames>Wakelin SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>BA3B36F2514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19381B67-1624-40CC-B854-E601EBF73CB2</gtr:id><gtr:title>Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50c2a528a87bc40c7305525cdd8d0c79"><gtr:id>50c2a528a87bc40c7305525cdd8d0c79</gtr:id><gtr:otherNames>Sandig H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>55EB9F4B0F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41776284-CDD4-48F0-AA4D-84C732B70617</gtr:id><gtr:title>Identifying and hurdling obstacles to translational research.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae7979792fa37c6ccd925b8ea628d6f"><gtr:id>fae7979792fa37c6ccd925b8ea628d6f</gtr:id><gtr:otherNames>Sabroe I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>15CA5A73559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55B1A84F-E9BB-4446-9717-DE58C5D879DA</gtr:id><gtr:title>The role of TLR activation in inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae7979792fa37c6ccd925b8ea628d6f"><gtr:id>fae7979792fa37c6ccd925b8ea628d6f</gtr:id><gtr:otherNames>Sabroe I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>591AC318B1C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC47B569-5290-4446-B039-6E41330E8EB3</gtr:id><gtr:title>Granulocyte apoptosis in the pathogenesis and resolution of lung disease.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cc9bed3eebbf906bf3a4af07c782d78"><gtr:id>7cc9bed3eebbf906bf3a4af07c782d78</gtr:id><gtr:otherNames>Bianchi SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>8EB3F89BB7D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C9CF077-1896-4E99-AC1F-CE3A35DA2876</gtr:id><gtr:title>Basic science of the innate immune system and the lung.</gtr:title><gtr:parentPublicationTitle>Paediatric respiratory reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/414028c2d7850c5efc94d6ee90c9a8c1"><gtr:id>414028c2d7850c5efc94d6ee90c9a8c1</gtr:id><gtr:otherNames>Chaudhuri N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1526-0542</gtr:issn><gtr:outcomeId>5DB3957783A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F05CE061-60FB-4231-994B-3654B8CE586F</gtr:id><gtr:title>Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35319da115a6ef0296e74a6594e5b7f5"><gtr:id>35319da115a6ef0296e74a6594e5b7f5</gtr:id><gtr:otherNames>Walmsley SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>pm_12741_21_21317538</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECC7B4F5-17A6-4C3D-AC91-81D691AEB2C3</gtr:id><gtr:title>Diesel exhaust particles override natural injury-limiting pathways in the lung.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Lung cellular and molecular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/414028c2d7850c5efc94d6ee90c9a8c1"><gtr:id>414028c2d7850c5efc94d6ee90c9a8c1</gtr:id><gtr:otherNames>Chaudhuri N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1040-0605</gtr:issn><gtr:outcomeId>kaWYz6BVmCm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF19B5C0-D418-49C9-8BE0-9C5FD99E85DB</gtr:id><gtr:title>Pathological networking: a new approach to understanding COPD.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae7979792fa37c6ccd925b8ea628d6f"><gtr:id>fae7979792fa37c6ccd925b8ea628d6f</gtr:id><gtr:otherNames>Sabroe I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>896AC19EB0B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33CCD98D-EB4C-43C7-A426-3BA529A3D3C6</gtr:id><gtr:title>Incapacitating the immune system in cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae7979792fa37c6ccd925b8ea628d6f"><gtr:id>fae7979792fa37c6ccd925b8ea628d6f</gtr:id><gtr:otherNames>Sabroe I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>7EDCF9013C1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EF8F699-842E-467D-9EAB-CCC5CE88737A</gtr:id><gtr:title>Translational mini-review series on Toll-like receptors: networks regulated by Toll-like receptors mediate innate and adaptive immunity.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce6d578dd442ed283224a3e514f486d3"><gtr:id>ce6d578dd442ed283224a3e514f486d3</gtr:id><gtr:otherNames>Parker LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>86B5CD149F6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86452587-4017-4474-ABCA-F5382665F8B7</gtr:id><gtr:title>Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cc9bed3eebbf906bf3a4af07c782d78"><gtr:id>7cc9bed3eebbf906bf3a4af07c782d78</gtr:id><gtr:otherNames>Bianchi SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>D5A28F40D95</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83ADB176-0342-447A-8F94-C810BD479F4C</gtr:id><gtr:title>Staphylococcus aureus induces eosinophil cell death mediated by a-hemolysin.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/701f833924554817b65818c42b70aa53"><gtr:id>701f833924554817b65818c42b70aa53</gtr:id><gtr:otherNames>Prince LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12741_21_22355374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45A42DA9-89EC-469A-8BCF-5BEF01B30E83</gtr:id><gtr:title>Temporal interleukin-1beta secretion from primary human peripheral blood monocytes by P2X7-independent and P2X7-dependent mechanisms.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af9cf1603ba8689b71fea78eea52b3db"><gtr:id>af9cf1603ba8689b71fea78eea52b3db</gtr:id><gtr:otherNames>Ward JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>2738FCCD55E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E159C557-3625-48B6-8074-68D7C0D6E96C</gtr:id><gtr:title>Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ce6f10cbeb290dea52c7b9dc3de967a"><gtr:id>8ce6f10cbeb290dea52c7b9dc3de967a</gtr:id><gtr:otherNames>Vaughan KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>A5879BF220A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF11A09E-6BB2-40B9-848D-C22E4DEE8867</gtr:id><gtr:title>The rise and rise of Staphylococcus aureus: laughing in the face of granulocytes.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a8f04162cf94c264340ddf47b88a333"><gtr:id>8a8f04162cf94c264340ddf47b88a333</gtr:id><gtr:otherNames>Anwar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>2963C9A14F8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C920D26-3FA6-4536-A30C-0BD74BFF54CF</gtr:id><gtr:title>Pathways regulating lipopolysaccharide-induced neutrophil survival revealed by lentiviral transduction of primary human neutrophils.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bceed23e31a217e9f8ecea149a8b7e3"><gtr:id>2bceed23e31a217e9f8ecea149a8b7e3</gtr:id><gtr:otherNames>Dick EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>10C2A97D7D0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B90C043-5555-4C69-8DF8-4821DE527E23</gtr:id><gtr:title>Translational mini-review series on immunology of vascular disease: inflammation, infections and Toll-like receptors in cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af9cf1603ba8689b71fea78eea52b3db"><gtr:id>af9cf1603ba8689b71fea78eea52b3db</gtr:id><gtr:otherNames>Ward JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>01244FF1441</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC08BAEA-DC49-4322-91E4-755E967B9CCE</gtr:id><gtr:title>A Bayesian approach to copy-number-polymorphism analysis in nuclear pedigrees.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1549f21f0180729a6ecef5c5e30da0fc"><gtr:id>1549f21f0180729a6ecef5c5e30da0fc</gtr:id><gtr:otherNames>Kosta K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>985C0BB556D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>211891EC-D8A7-4B2D-9D97-CD1724CDAAFE</gtr:id><gtr:title>NR4A orphan nuclear receptor family members, NR4A2 and NR4A3, regulate neutrophil number and survival.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/701f833924554817b65818c42b70aa53"><gtr:id>701f833924554817b65818c42b70aa53</gtr:id><gtr:otherNames>Prince LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5959013d6cd5d0.12784105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78730C61-81A9-4D8B-ADB9-50AAD88A6A2D</gtr:id><gtr:title>Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease.</gtr:title><gtr:parentPublicationTitle>Journal of endotoxin research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffc63809070013a47cc2af8327691562"><gtr:id>ffc63809070013a47cc2af8327691562</gtr:id><gtr:otherNames>Medvedev AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0968-0519</gtr:issn><gtr:outcomeId>8D0B1F308DB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDA088B2-87F5-4DC6-BE37-51889C64D16A</gtr:id><gtr:title>Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ba2ee40a2d0300876ef133188f77aec"><gtr:id>6ba2ee40a2d0300876ef133188f77aec</gtr:id><gtr:otherNames>Morris GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>7879C49F101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7D20CF7-DB87-4FB7-9B23-C40F952FE80F</gtr:id><gtr:title>Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8af0136ba2a4b82a4a85c237feb342aa"><gtr:id>8af0136ba2a4b82a4a85c237feb342aa</gtr:id><gtr:otherNames>West PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>A30D2DDED8F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3A12F44-CABA-4EC1-BBE0-F864CF6508AC</gtr:id><gtr:title>The generation of highly purified primary human neutrophils and assessment of apoptosis in response to Toll-like receptor ligands.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce6d578dd442ed283224a3e514f486d3"><gtr:id>ce6d578dd442ed283224a3e514f486d3</gtr:id><gtr:otherNames>Parker LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>E90CE918474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3CE28C0-5DB0-44AA-A8D7-E980AE09AC9E</gtr:id><gtr:title>Reducing the toll of inflammatory lung disease.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/414028c2d7850c5efc94d6ee90c9a8c1"><gtr:id>414028c2d7850c5efc94d6ee90c9a8c1</gtr:id><gtr:otherNames>Chaudhuri N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>B0F2E04B6E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>670C48A8-80F8-4E12-88E4-BDA0D13E008E</gtr:id><gtr:title>A central role for monocytes in Toll-like receptor-mediated activation of the vasculature.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af9cf1603ba8689b71fea78eea52b3db"><gtr:id>af9cf1603ba8689b71fea78eea52b3db</gtr:id><gtr:otherNames>Ward JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>23488DCED28</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C42D6ED-A59F-4B15-A041-7F5B3EF67B9C</gtr:id><gtr:title>Toll-like receptor (TLR)-based networks regulate neutrophilic inflammation in respiratory disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae7979792fa37c6ccd925b8ea628d6f"><gtr:id>fae7979792fa37c6ccd925b8ea628d6f</gtr:id><gtr:otherNames>Sabroe I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>C7E861A67D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8086C6C8-BE2B-4264-B938-E108363D61A5</gtr:id><gtr:title>Practical and conceptual models of chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae7979792fa37c6ccd925b8ea628d6f"><gtr:id>fae7979792fa37c6ccd925b8ea628d6f</gtr:id><gtr:otherNames>Sabroe I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1546-3222</gtr:issn><gtr:outcomeId>73C1A7089FC</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G116/170</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>